Immunovant Announces Pricing of $550 Million Common Stock Financing

Core Viewpoint - Immunovant, Inc. has announced an underwritten offering of common stock expected to raise approximately $550 million to support its operations and the potential commercial launch of IMVT-1402 for Graves' Disease [1][2]. Group 1: Offering Details - The company is offering 26.2 million shares at a price of $21.00 per share, with the offering expected to close around December 12, 2025, pending customary closing conditions [3]. - Roivant Sciences Ltd., the controlling stockholder of Immunovant, has agreed to purchase shares in this offering [1]. Group 2: Financial Implications - The proceeds from the offering, combined with existing cash and cash equivalents, are anticipated to be sufficient to fund operating expenses and capital expenditures through the potential commercial launch of IMVT-1402 [2].